Henry O. Gosebruch net worth and biography

Henry Gosebruch Biography and Net Worth

EVP of AbbVie

Henry Gosebruch is Executive Vice President, Chief Strategy Officer at AbbVie, responsible for corporate strategy, business development and acquisitions, search and evaluation, alliance management and AbbVie Ventures.

Since joining AbbVie in December 2015, Mr. Gosebruch and his team have completed more than 75 partnering, collaboration, mergers & acquisitions (M&A) and venture transactions to bolster AbbVie’s commercial franchises and pipeline of innovative preclinical and clinical development programs, working closely with AbbVie colleagues globally.

Prior to joining AbbVie, Mr. Gosebruch was Co-Head of J.P. Morgan’s North American M&A Group based in New York. He worked on numerous complex M&A transactions involving companies in more than 20 countries.

Mr. Gosebruch serves on the board of Aptinyx. He is also member of the Advisory Board for the Life Sciences & Management Program at the University of Pennsylvania. At AbbVie, he is the executive chair of the Asian Leadership Network Employee Resource Group.

What is Henry O. Gosebruch's net worth?: The estimated net worth of Henry O. Gosebruch is at least $2.59 million as of September 19th, 2023. Mr. Gosebruch owns 15,000 shares of AbbVie stock worth more than $2,591,625 as of April 17th. This net worth evaluation does not reflect any other assets that Mr. Gosebruch may own. Learn More about Henry O. Gosebruch's net worth.
How do I contact Henry O. Gosebruch?: The corporate mailing address for Mr. Gosebruch and other AbbVie executives is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. AbbVie can also be reached via phone at (847) 932-7900. Learn More on Henry O. Gosebruch's contact information.
Has Henry O. Gosebruch been buying or selling shares of AbbVie?: Henry O. Gosebruch has not been actively trading shares of AbbVie during the last ninety days. Most recently, Henry O. Gosebruch sold 83,960 shares of the business's stock in a transaction on Monday, May 16th. The shares were sold at an average price of $155.00, for a transaction totalling $13,013,800.00. Following the completion of the sale, the executive vice president now directly owns 16,623 shares of the company's stock, valued at $2,576,565. Learn More on Henry O. Gosebruch's trading history.
Who are AbbVie's active insiders?: AbbVie's insider roster includes Carlos Alban (Vice Chairman), Roxanne Austin (Director), Kevin Buckbee (SVP), Nicholas Donoghoe (SVP), Brian Durkin (VP), Richard Gonzalez (CEO), Henry Gosebruch (EVP), Robert Michael (Vice Chairman), Scott Reents (Sr. VP & CFO ), Scott Reents (CFO), Timothy Richmond (EVP), Azita Saleki-Gerhardt (EVP), Laura Schumacher (Vice Chairman), Michael Severino (Vice Chairman), Perry Siatis (EVP), Elaine Sorg (SVP), Jeffrey Stewart (EVP), and Carrie Strom (SVP). Learn More on AbbVie's active insiders.
Are insiders buying or selling shares of AbbVie?: During the last year, insiders at the sold shares 7 times. They sold a total of 464,616 shares worth more than $85,637,938.10. The most recent insider tranaction occured on March, 31st when EVP Jeffrey Ryan Stewart sold 58,832 shares worth more than $12,359,426.56. Insiders at AbbVie own 0.3% of the company. Learn More about insider trades at AbbVie.
Information on this page was last updated on 3/31/2025.

Henry O. Gosebruch Insider Trading History at AbbVie

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/16/2022	Sell	83,960	$155.00	$13,013,800.00	16,623
3/1/2022	Sell	15,000	$148.26	$2,223,900.00
7/29/2019	Buy	30,000	$67.28	$2,018,400.00	75,763
11/29/2018	Sell	42,450	$90.10	$3,824,745.00	30,350
10/30/2017	Sell	18,300	$90.55	$1,657,065.00	81,287
7/31/2017	Sell	18,000	$70.09	$1,261,620.00	96,074

Henry O. Gosebruch Buying and Selling Activity at AbbVie

AbbVie Company Overview

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Today's Range

Now: $172.78

$171.91

$175.20

50 Day Range

MA: $198.85

$171.57

$216.62

2 Week Range

Now: $172.78

$153.58

$218.66

Volume

8,474,425 shs

Average Volume

5,997,458 shs

Market Capitalization

$305.64 billion

P/E Ratio

71.99

Dividend Yield

3.66%

Beta

0.55